DK2726510T3 - Dobbelt målretning - Google Patents

Dobbelt målretning Download PDF

Info

Publication number
DK2726510T3
DK2726510T3 DK12725311.0T DK12725311T DK2726510T3 DK 2726510 T3 DK2726510 T3 DK 2726510T3 DK 12725311 T DK12725311 T DK 12725311T DK 2726510 T3 DK2726510 T3 DK 2726510T3
Authority
DK
Denmark
Prior art keywords
dual targeting
targeting
dual
Prior art date
Application number
DK12725311.0T
Other languages
English (en)
Inventor
Roland Beckmann
Hobolt Kristian Jensen
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Application granted granted Critical
Publication of DK2726510T3 publication Critical patent/DK2726510T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46Hybrid immunoglobulins
    • C07K16/468Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203Gram-negative bacteria
    • C07K16/1228Enterobacterales (O), e.g. Citrobacter (G), Serratia (G), Proteus (G), Providencia (G), Morganella (G) or Yersinia (G)
    • C07K16/1232Escherichia (G)
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/243Colony Stimulating Factors
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244Interleukins [IL]
    • C07K16/248IL-6
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/10Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034Isolating an individual clone by screening libraries
    • C12N15/1058Directional evolution of libraries, e.g. evolution of libraries is achieved by mutagenesis and screening or selection of mixed population of organisms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565Complementarity determining region [CDR]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Ecology (AREA)
  • Physics & Mathematics (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Saccharide Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DK12725311.0T 2011-05-27 2012-05-29 Dobbelt målretning DK2726510T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP11004373 2011-05-27
PCT/EP2012/002279 WO2012163520A1 (en) 2011-05-27 2012-05-29 Dual targeting

Publications (1)

Publication Number Publication Date
DK2726510T3 true DK2726510T3 (da) 2023-05-15

Family

ID=46207961

Family Applications (1)

Application Number Title Priority Date Filing Date
DK12725311.0T DK2726510T3 (da) 2011-05-27 2012-05-29 Dobbelt målretning

Country Status (19)

Country Link
US (4) US20140206846A1 (da)
EP (1) EP2726510B1 (da)
JP (2) JP2014516542A (da)
CN (2) CN103930445B (da)
AU (1) AU2012265156B2 (da)
CA (1) CA2853383C (da)
DK (1) DK2726510T3 (da)
ES (1) ES2943577T3 (da)
FI (1) FI2726510T3 (da)
HR (1) HRP20230411T1 (da)
HU (1) HUE061692T2 (da)
IL (1) IL229649B (da)
LT (1) LT2726510T (da)
PL (1) PL2726510T3 (da)
PT (1) PT2726510T (da)
RS (1) RS64179B1 (da)
SG (2) SG10201604279TA (da)
SI (1) SI2726510T1 (da)
WO (1) WO2012163520A1 (da)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112015013020A2 (pt) 2012-12-05 2017-07-11 Dutalys Gmbh método de geração de anticorpos biespecíficos, coleção de anticorpos ou seus fragmentos funcionais, de sequências de ácidos nucleicos, de vetores e de células hospedeiras, método de produção da coleção de anticorpos e de identificação de um anticorpo, anticorpo ou fragmento funcional e anticorpo biespecífico
JP7325166B2 (ja) * 2013-12-20 2023-08-14 ジェネンテック, インコーポレイテッド 二重特異性抗体
KR20170010863A (ko) 2014-07-01 2017-02-01 화이자 인코포레이티드 이중특이성 이종이량체성 디아바디 및 이의 용도
EP3201227A4 (en) 2014-09-29 2018-04-18 Duke University Bispecific molecules comprising an hiv-1 envelope targeting arm
WO2016149710A2 (en) 2015-03-19 2016-09-22 Duke University Hiv-1 neutralizing antibodies and uses thereof
AU2016232693B2 (en) 2015-03-19 2021-08-12 Duke University HIV-1 neutralizing antibodies and uses thereof
WO2016149698A2 (en) 2015-03-19 2016-09-22 Duke University Hiv-1 neutralizing antibodies and uses thereof (v3 antibodies)
US10450368B2 (en) 2015-03-19 2019-10-22 Duke University HIV-1 neutralizing antibodies and uses thereof (CD4bs antibodies)
CN109791149A (zh) 2016-09-30 2019-05-21 豪夫迈·罗氏有限公司 用于功能分析多特异性分子的基于spr的双重结合测定法
EP3330289A1 (en) 2016-12-02 2018-06-06 Friedrich-Alexander-Universität Erlangen-Nürnberg A cd33-, cd16- and cd123-specific single chain triplebody
GB201711208D0 (en) 2017-07-12 2017-08-23 Iontas Ltd Ion channel inhibitors
US12071476B2 (en) * 2018-03-02 2024-08-27 Kodiak Sciences Inc. IL-6 antibodies and fusion constructs and conjugates thereof
WO2020127873A1 (en) * 2018-12-21 2020-06-25 F. Hoffmann-La Roche Ag Antibody that binds to vegf and il-1beta and methods of use
CN119716045A (zh) 2018-12-30 2025-03-28 豪夫迈·罗氏有限公司 基于pH梯度SPR的结合测定
WO2020200941A1 (en) 2019-03-29 2020-10-08 F. Hoffmann-La Roche Ag Spr-based binding assay for the functional analysis of multivalent molecules
JP7412440B2 (ja) 2019-03-29 2024-01-12 エフ. ホフマン-ラ ロシュ アーゲー アビド結合多重特異性抗体を作製する方法
CA3140287A1 (en) 2019-06-19 2020-12-24 Johannes Auer Method for the generation of a trivalent antibody expressing cell by targeted integration of multiple expression cassettes in a defined organization
CA3140323A1 (en) 2019-06-19 2020-12-24 Johannes Auer Method for the generation of a multivalent, bispecific antibody expressing cell by targeted integration of multiple expression cassettes in a defined organization
KR20220010019A (ko) 2019-06-19 2022-01-25 에프. 호프만-라 로슈 아게 정의된 조직에서 다중 발현 카세트의 표적화된 통합에 의해 2가 이중특이성 항체 발현 세포를 생성하는 방법
MX2021015648A (es) 2019-06-19 2022-02-03 Hoffmann La Roche Metodo para la generacion de una celula que expresa un anticuerpo multiespecifico multivalente mediante integracion dirigida de multiples casetes de expresion en una organizacion definida.
BR112021025425A2 (pt) 2019-06-19 2022-02-01 Hoffmann La Roche Método para produzir uma célula de mamífero recombinante e uso de mrna de recombinase cre
HUE071032T2 (hu) 2019-06-26 2025-07-28 Hoffmann La Roche Emlõs sejtvonalak SIRT-1 gén kiiktatásával
AU2020364071A1 (en) 2019-10-10 2022-05-26 Kodiak Sciences Inc. Methods of treating an eye disorder
WO2021084104A1 (en) 2019-10-30 2021-05-06 Bioinvent International Ab Tetravalent antibody molecules
JP7570421B2 (ja) 2020-01-02 2024-10-21 エフ. ホフマン-ラ ロシュ アーゲー Ada応答特定アッセイ
EP4126940A1 (en) 2020-03-30 2023-02-08 F. Hoffmann-La Roche AG Antibody that binds to vegf and pdgf-b and methods of use
PE20230986A1 (es) 2020-09-04 2023-06-21 Hoffmann La Roche Anticuerpo que se une a vegf-a y ang2, y metodos de uso
AU2021347580A1 (en) 2020-09-24 2023-04-06 F. Hoffmann-La Roche Ag Mammalian cell lines with gene knockout
CN116670282A (zh) 2020-12-22 2023-08-29 豪夫迈·罗氏有限公司 靶向xbp1的寡核苷酸
EP4281474A4 (en) * 2021-01-21 2025-03-05 Biolojic Design Ltd. Dual binding antibodies, methods of producing dual binding antibodies, and uses thereof
WO2022175217A1 (en) 2021-02-18 2022-08-25 F. Hoffmann-La Roche Ag Method for resolving complex, multistep antibody interactions
WO2022214565A1 (en) 2021-04-09 2022-10-13 F. Hoffmann-La Roche Ag Process for selecting cell clones expressing a heterologous polypeptide
CA3217029A1 (en) * 2021-05-30 2022-12-08 Biolojic Design Ltd. Engineered dual binding antibodies and uses thereof
CN118401674A (zh) 2021-12-21 2024-07-26 豪夫迈·罗氏有限公司 用于确定水解活性的方法
WO2023202967A1 (en) 2022-04-19 2023-10-26 F. Hoffmann-La Roche Ag Improved production cells
AR129268A1 (es) * 2022-05-11 2024-08-07 Hoffmann La Roche Anticuerpo que se une a vegf-a e il6 y métodos de uso
CN119630690A (zh) 2022-06-03 2025-03-14 豪夫迈·罗氏有限公司 改进的生产细胞
EP4602371A1 (en) 2022-10-12 2025-08-20 F. Hoffmann-La Roche AG Method for classifying cells
KR20250110226A (ko) 2022-11-23 2025-07-18 에프. 호프만-라 로슈 아게 재조합 단백질 발현을 증가시키는 방법
WO2024231320A1 (en) 2023-05-08 2024-11-14 F. Hoffmann-La Roche Ag Targeted interferon alpha fusion proteins and methods of use
CN121693516A (zh) 2023-08-09 2026-03-17 豪夫迈·罗氏有限公司 单特异性和多特异性抗trem2抗体、其方法及用途
CN121666400A (zh) 2023-08-09 2026-03-13 豪夫迈·罗氏有限公司 单特异性和多特异性抗trem2抗体、其方法和用途
WO2025099120A1 (en) 2023-11-09 2025-05-15 F. Hoffmann-La Roche Ag Multispecific antibodies with conditional activity

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
ATE219517T1 (de) 1995-08-18 2002-07-15 Morphosys Ag Protein-/(poly)peptidbibliotheken
US7883704B2 (en) * 1999-03-25 2011-02-08 Abbott Gmbh & Co. Kg Methods for inhibiting the activity of the P40 subunit of human IL-12
MXPA02012867A (es) 2000-06-29 2003-09-05 Abbott Lab Anticuerpos de especificidad doble y metodos para la elaboracion y el uso de los mismos.
AU2002319402B2 (en) * 2001-06-28 2008-09-11 Domantis Limited Dual-specific ligand and its use
US9321832B2 (en) 2002-06-28 2016-04-26 Domantis Limited Ligand
US7749724B2 (en) 2005-07-05 2010-07-06 Washington State University Fluorogenic selective and differential medium for isolation of Enterobacter sakazakii
WO2007112940A2 (en) 2006-03-31 2007-10-11 Ablynx N.V. Albumin-derived amino acid sequence, use thereof for increasing the half-life of therapeutic proteins and of other therapeutic compounds and entities, and constructs comprising the same
DK2059533T3 (da) * 2006-08-30 2013-02-25 Genentech Inc Multispecifikke antistoffer

Also Published As

Publication number Publication date
LT2726510T (lt) 2023-05-10
SG10201604279TA (en) 2016-07-28
CN103930445A (zh) 2014-07-16
IL229649B (en) 2019-08-29
US20140206846A1 (en) 2014-07-24
WO2012163520A1 (en) 2012-12-06
PT2726510T (pt) 2023-05-03
RS64179B1 (sr) 2023-05-31
WO2012163520A4 (en) 2013-01-24
AU2012265156A1 (en) 2014-01-16
PL2726510T3 (pl) 2023-05-29
NZ619409A (en) 2016-05-27
SG195196A1 (en) 2013-12-30
CA2853383C (en) 2021-04-06
US20180094078A1 (en) 2018-04-05
JP6659626B2 (ja) 2020-03-04
ES2943577T3 (es) 2023-06-14
US20230279155A1 (en) 2023-09-07
US20210079119A1 (en) 2021-03-18
JP2014516542A (ja) 2014-07-17
EP2726510B1 (en) 2023-03-08
SI2726510T1 (sl) 2023-06-30
AU2012265156B2 (en) 2017-01-19
EP2726510A1 (en) 2014-05-07
FI2726510T3 (fi) 2023-05-04
IL229649A0 (en) 2014-01-30
HRP20230411T1 (hr) 2023-07-07
CN112661848A (zh) 2021-04-16
CA2853383A1 (en) 2012-12-06
CN103930445B (zh) 2021-03-09
JP2017221200A (ja) 2017-12-21
HUE061692T2 (hu) 2023-08-28

Similar Documents

Publication Publication Date Title
DK2744810T4 (da) Tenofovir-alafenamid-hemifumarat
EP3656792C0 (en) FC IMMUNOGLOBULIN VARIANTS
EP2715659A4 (en) ABOUT FEED
SI2726510T1 (sl) Dvojno ciljanje
DK2769050T3 (da) Propsensor
DE102011100082A8 (de) Traygreifvorrichtung
EP2752374A4 (en) gooseneck
EP2795884A4 (en) Audio conferencing
BR112014000879A2 (pt) deflegmador
DK3272861T3 (da) Alpha-galactosidase-sammensætninger
EP2701512A4 (en) Aldosterone synthase inhibitors
CO6960543A2 (es) 2-tiopirimidinonas
EP2786752A4 (en) Ropinirole-containing adhesive patch
EP2723481A4 (en) FLOW COMPENSATOR
DK3141251T3 (da) Koloskopi - forberedelse
EP2663189A4 (en) Combination
EP2708561A4 (en) BIO-PIN
EP2695208A4 (en) MICRO THERMOCOUPLE
EP2715068A4 (en) Tunneling apparatus
EP2738148A4 (en) RECIPROCAL LOCKING BLOCK
EP2762923A4 (en) RADIATION MEASURING DEVICE
DE112011104936A5 (de) Stanzstauchniet
EP2760803A4 (en) Geopolymer product
DE112012000958A5 (de) Handsäge
EP2771685A4 (en) BIOMARKERS OF CANCER